• Overview
  Quotes Prices Key Stats News Press Releases Sentiment
• Charts
  Chart Technicals
• Company
  Splits Dividends Recommendations Price Target Insider Trades Holders Peers Filings Notes due Fail to deliver ESG Score Executive Compensation Profile
• Earnings
  Price Reaction Earnings Estimates Trends Call Transcripts
• Financials
  Fundamentals DCF Beta
• Options
  Option Chain Option Strategies Put/Call Ratios
• Analysis
  Up/Down Intra-day Events Performance Recovery Returns Price Distribution Unusual Volume Best Days Data Correlations Seasonality Volatility Trader Stats

Summary

News

07/02 17:05 EST - investorplace.com
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.

06/20 10:45 EST - zacks.com
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.

06/17 08:45 EST - newsfilecorp.com
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM).

06/17 08:00 EST - prnewswire.com
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors - Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy - Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors NEW YORK , June 17, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models was presented at the 2024 European Hematology Association (EHA) Congress held June 13 – 16, 2024, in Madrid, Spain. Actinium studied Actimab-A in combination with the leading menin inhibitors, revumenib (Syndax Pharmaceuticals, Inc.) and ziftomenib (Kura Oncology, Inc.), which are being developed for patients with KMT2A rearrangements and NMP1 mutations, which are present in approximately 10% and 30% of AML patients, respectively.

06/14 08:30 EST - prnewswire.com
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
-  Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial -  Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial NEW YORK , June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The two presentations at EHA highlighted outcomes in patients with active relapsed or refractory acute myeloid leukemia (r/r AML) enrolled in the SIERRA trial who had a TP53 mutation and long-term efficacy results in this older patient population.

06/11 08:30 EST - prnewswire.com
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia - Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and venetoclax treated patients - SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination NEW YORK , June 11, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 – 11, 2024, in Toronto, Canada. Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload.

06/10 19:22 EST - investorplace.com
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.

06/10 08:30 EST - prnewswire.com
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutation Iomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% access to bone marrow transplant Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications NEW YORK , June 10, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The presentations featured results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients with active relapsed or refractory acute myeloid leukemia (r/r AML) for a potentially curative bone marrow transplant (BMT).

06/07 07:30 EST - investorplace.com
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed.

05/15 08:30 EST - prnewswire.com
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
-  KOL and principal investigator, Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar -  Webinar to be held on Monday, May 20 th at 8:00 AM ET NEW YORK , May 15, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced it will host a KOL webinar on Monday, May 20, 2024, at 8:00 AM ET. The call will highlight and discuss Actinium's recently announced Iomab-ACT commercial CAR T-cell trial being conducted at the University of Texas Southwestern (UTSW) including the study design, objectives and potential commercial opportunity for Iomab-ACT.

05/14 18:38 EST - prnewswire.com
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial - Long-term efficacy results in older patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial NEW YORK , May 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B have been accepted for an oral presentation and poster presentation at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving an Iomab-B led bone marrow transplant (BMT) to those of patients receiving physician's choice of care in the control arm.

05/14 10:24 EST - investorplace.com
3 Cheap Biotech Stocks to Buy Now: May 2024
The biotech industry is notably risky, but can produce stocks that see massive gains within a day. How can this happen?

05/13 08:30 EST - prnewswire.com
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
-       Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey -       Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment -       Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications NEW YORK , May 13, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that five abstracts have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The abstracts will feature results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients for a potentially curative bone marrow transplant (BMT) and results from a Phase 1b trial of Actimab-A, a CD33 targeting ARC with the Actinium-225 payload, in combination with the chemotherapy regimen CLAG-M.

05/12 09:32 EST - seekingalpha.com
A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising results in clinical trials, increasing survival rates for elderly patients and targeting specific leukemia-related antigens. Strategic partnerships, particularly with Immedica AB for the EUMENA market, aim to strengthen Actinium's global market presence.

05/07 08:00 EST - prnewswire.com
Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinar Expansion of Iomab-ACT program with commercial CAR-T supported by ongoing MSKCC clinical trial with success implying a potential billion-dollar market opportunity in lymphodepletion Webinar to be held on Monday, May 20 th at 8:00 AM ET NEW YORK , May 7, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced it will host a KOL call on Monday, May 20, 2024, at 8:00 AM ET to provide updates and highlight its recently announced clinical trial to study Iomab-ACT with a leading FDA approved CAR-T cell therapy at the University of Texas Southwestern (UTSW). Iomab-ACT is an ARC that targets CD45, a marker expressed on blood cancer cells and immune cells that is intended to enable conditioning prior to cell and gene therapies such as CAR T-cell therapy and replace the non-targeted chemotherapy that is currently used for conditioning.

04/18 08:00 EST - prnewswire.com
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia -- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) NEW YORK , April 18, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17. The results showed that an Iomab-B led bone marrow transplant (BMT) results in higher rates of remissions and durable Complete Remission (dCR), which is the primary endpoint of the SIERRA trial, as well as significant improvement in overall survival in TP53 positive patients.

04/15 12:54 EST - investorplace.com
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.

04/01 08:00 EST - prnewswire.com
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
-  The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis -  Represents the eleventh oral presentation of the Phase 3 SIERRA results demonstrating continued recognition of the high potential for Iomab-B led allogeneic bone marrow transplant by the bone marrow transplant community   NEW YORK , April 1, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy conditioning agent comprised of an anti-CD45 monoclonal antibody and Iodine-131 radioisotope payload.

03/26 07:18 EST - prnewswire.com
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billion in 2023 and cell and gene therapies forecasted to reach over ninety-thousand patients annually by 2030 Iomab-ACT is the first targeted radiotherapy agent intended to be used to condition patients for cell and gene therapies to replace the need for non-targeted chemotherapy Iomab-ACT clinical data to date shows CAR T-cell persistence and ability to deplete targeted immune cells including lymphocytes resulting in negligible rates of CAR-T toxicities ICANS and CRS NEW YORK , March 26, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the University of Texas Southwestern Medical Center (UT Southwestern) will lead a clinical trial studying Actinium's Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy. UT Southwestern will start recruiting patients following FDA's review and clearance of the study.

03/15 06:15 EST - investorplace.com
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
Few stock sectors offer soar-or-sink possibilities like biotechnology stocks do. If you're in the market for an intriguing biotech pick and can manage high risk, take a look at Actinium Pharmaceuticals (NYSEAMERICAN: ATNM )stock.